长春瑞滨软胶囊单药节拍化疗一线治疗老年非小细胞肺癌临床疗效观察

林金兰; 郭天兴; 潘小杰; 徐振武

doi:10.3971/j.issn.1000-8578.2018.18.0841

长春瑞滨软胶囊单药节拍化疗一线治疗老年非小细胞肺癌临床疗效观察

Clinical Observation of Metronomic Oral Vinorelbine Monotherapy as First-line Treatment on Elderly Patients with Advanced Non-small Cell Lung Cancer

摘要

摘要:
目的探讨口服长春瑞滨软胶囊单药节拍化疗在老年非小细胞肺癌患者中的临床疗效及生存时间分析。
方法选择56例年龄≥75岁初治老年非小细胞肺癌患者, 给以口服长春瑞滨软胶囊50 mg每次, 每周3次单药节拍化疗, 观察临床疗效、不良反应及总生存期和无进展生存期。
结果全部患者疗效评价CR 1例(1.8%), PR 9例(16.1%), ORR为17.9%;SD 22例(39.3%), 并且稳定时间人均达12周以上, DCR达57.2%;中位无进展生存期5月(3~22月), 中位总生存期9月(4~31月), 1年生存率为35.7%(20/56), 2年生存率为16.1%(9/56), 3~4级不良反应出现较少。
结论应用长春瑞滨软胶囊单药节拍化疗安全可靠, 可有效改善生活质量, 为老年非小细胞肺癌患者临床综合治疗决策提供了新的思路。

Abstract:
Objective To investigate the clinical effect and survival analysis of metronomic oral vinorelbine monotherapy on elderly patients with advanced non-small cell lung cancer (NSCLC).
Methods We involved 56 chemotherapy-naive elderly patients(≥75 yrs) with stage ⅢB-Ⅳ NSCLC who received oral vinorelbine 50 mg per time, three times per week (Monday-Wednesday-Friday) continuously, until disease progression, unacceptable toxicity or patient refusal.Observation endpoints were overall response rate (ORR), overall survival(OS) and progression free survival(PFS).
Results ORR was 17.9% with 9 cases(16.1%) of PR and 1 case(1.8%) of CR; 22 patients(39.3%) experienced stable disease lasting more than 12 weeks, leading to an overall DCR of 57.2%.Median progression-free survival was 5 months (range 3-22 months) and median overall survival was 9 months (range 4-31 months).Treatment was well tolerated with rare serious toxicity(grade 3-4).
Conclusion Metronomic oral vinorelbine monotherapy is safe, reliable and could improve patients' life of quality, which provide an interesting option for clinic therapy decision on elderly patients with advanced NSCLC.

HTML全文

参考文献(11)

施引文献

资源附件(0)